The use of artificial intelligence (AI) in the pharmaceutical sector is transforming drug discovery, development, and regulatory approval processes, creating significant opportunities for the emerging techbio industry. According to a report by Tecknoworks, the global AI in pharmaceuticals market was valued at $1.8 billion in 2023 and is expected to grow substantially to $13.1 billion by 2034, representing a compound annual growth rate (CAGR) of 18.8% between 2024 and 2034.
The company we are profiling today is Caris Life Sciences, Inc. (CAI), a patient-centric AI TechBio company that uses molecular data and artificial intelligence/machine learning algorithms to advance precision medicine, with a primary focus on oncology and services for clinical, academic, and biopharma markets.
For comments and feedback contact: editorial@rttnews.com
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.